Table 1a.
Clinical characteristics of patients undergoing single UCBT
| Characteristic | All | With ATG | Without ATG | p |
|---|---|---|---|---|
| N | 810 | 521 | 289 | |
| Number of centers | 105 | 88 | 68 | |
| Age, median (range), years | 6 (<1–18) | 5 (<1–18) | 7 (1–18) | <0.001 |
| Age at UCBT, years | <0.001 | |||
| 0–4 | 346 (43%) | 248 (48%) | 98 (34%) | |
| 5–9 | 275 (34%) | 164 (31%) | 111 (38%) | |
| 10–14 | 148 (18%) | 90 (17%) | 58 (20%) | |
| 15–17 | 41 (5%) | 19 (4%) | 22 (8%) | |
| Gender | 0.37 | |||
| Male | 451 (56%) | 284 (55%) | 167 (58%) | |
| Female | 359 (44%) | 237 (45%) | 122 (42%) | |
| Karnofsky/Lansky score | 0.66 | |||
| < 90 | 141 (17%) | 93 (18%) | 48 (17%) | |
| 90–100 | 669 (83%) | 428 (82%) | 241 (83%) | |
| Race of recipient | 0.03 | |||
| Caucasian | 469 (58%) | 320 (61%) | 149 (52%) | |
| African-American | 77 (10%) | 49 (9%) | 28 (10%) | |
| Asian/Pacific Islander | 45 (6%) | 28 (5%) | 17 (6%) | |
| Hispanic | 176 (22%) | 97 (19%) | 79 (27%) | |
| Native American | 11 (1%) | 9 (2%) | 2 (< 1%) | |
| Missing | 32 (4%) | 18 (3%) | 14 (5%) | |
| CMV status of recipient | 0.16 | |||
| Negative | 412 (51%) | 278 (53%) | 134 (46%) | |
| Positive | 391 (48%) | 239 (46%) | 152 (53%) | |
| Missing | 7 (< 1%) | 4 (< 1%) | 3 (1%) | |
| Disease | <0.001 | |||
| AML | 356 (44%) | 255 (49%) | 101 (35%) | |
| ALL | 454 (56%) | 266 (51%) | 188 (65%) | |
| Disease status at UCBT | 0.07 | |||
| Early | 282 (35%) | 182 (35%) | 100 (35%) | |
| Intermediate | 412 (51%) | 253 (49%) | 159 (55%) | |
| Advanced | 114 (14%) | 84 (16%) | 30 (10%) | |
| Missing | 2 (<1%) | 2 (<1%) | 0 | |
| Donor-Recipient sex match | 0.71 | |||
| F-M | 215 (26%) | 141 (27%) | 74 (26%) | |
| F-F | 175 (22%) | 116 (22%) | 59 (20%) | |
| M-M | 234 (29%) | 142 (27%) | 92 (32%) | |
| M-F | 184 (23%) | 121 (23%) | 63 (22%) | |
| Missing | 2 (<1%) | 1 (<1%) | 1 (<1%) | |
| HLA-matching | 0.05 | |||
| 6/6 | 169 (21%) | 111 (21%) | 58 (20%) | |
| 5/6 | 382 (47%) | 230 (44%) | 152 (53%) | |
| 4/6 | 259 (32%) | 180 (34%) | 79 (27%) | |
| Total nucleated cell dose, pre-cryo, median (range) × 107/kg | 7 (3–56) | 7 (3–50) | 6 (3–56) | 0.03 |
| Total nucleated cell dose, pre-cryo, × 107/kg | <0.001 | |||
| 3–5 | 195 (24%) | 107 (21%) | 88 (30%) | |
| 5–8 | 223 (28%) | 133 (26%) | 90 (31%) | |
| ≥ 8 | 289 (36%) | 205 (39%) | 82 (39%) | |
| Missing | 103 (13%) | 76 (15%) | 27 (9%) | |
| Conditioning regimen | ||||
| Myeloablative | 810 (100%) | 521 (100%) | 289 (100%) | – |
| Reduced Intensity | 0 | 0 | 0 | |
| TBI used | 573 (71%) | 314 (60%) | 259 (90%) | <0.001 |
| GVHD prophylaxis | <0.001 | |||
| CNI + SIRO | 34 (4%) | 6 (1%) | 28 (10%) | |
| CNI + MMF | 327 (40%) | 151 (29%) | 176 (61%) | |
| CNI + MTX | 102 (13%) | 56 (11%) | 46 (16%) | |
| CNI + COR | 247 (30%) | 220 (42%) | 27 (9%) | |
| CNI ± other | 100 (12%) | 88 (17%) | 12 (4%) | |
| Year of UCBT | <0.001 | |||
| 2003–2005 | 202 (25%) | 184 (35%) | 18 (6%) | |
| 2006–2008 | 288 (36%) | 182 (35%) | 106 (37%) | |
| 2009–2012 | 320 (39%) | 155 (30%) | 165 (57%) |
Abbreviations: UCBT = Umbilical Cord Blood Transplant; GVHD = graft-vs.-host disease; CNI = Calcineurin Inhibitor (either Cyclosporine or Tacrolimus); SIRO = Sirolimus; MMF = Mycophenolate mofetil; MTX = Methotrexate; COR = Corticosteroids (systemic).